.
How Biosimilar Eye Drugs Are Reshaping Europe’s Ophthalmology Landscape
Celltrion’s recent rollout of the biosimilar Idencelt (active ingredient: aplicerept) marks a pivotal moment for the European market for age‑related macular degeneration (AMD) and other retinal diseases. By securing early NHS tenders in the UK and launching in Portugal, the company is testing a playbook that could become the industry standard.
Trend #1 – Accelerated NHS and EU Tender Processes
National health services across Europe are streamlining procurement to cut costs while maintaining quality. In the UK, the NHS’ centralized tendering system has already listed Idencelt as the only biosimilar on the official formulary for the North of England region, giving it a competitive edge over newer entrants.
Data from the European Federation of Pharmaceutical Industries and Associations (EFPIA) shows that biosimilar tender awards grew 23 % YoY in 2023, and experts project a 35 % increase by 2026. Companies that lock in contracts early can leverage “first‑in‑market” incentives and faster reimbursement pathways.
Trend #2 – Direct‑to‑Provider Sales Model Gains Traction
Celltrion’s “direct‑sale” strategy, honed through its oncology and autoimmune pipelines, is now being applied to ophthalmology. By bypassing third‑party distributors, the firm can maintain tighter control over pricing, education, and post‑marketing surveillance.
Case in point: In Germany, a comparable biosimilar for rheumatoid arthritis saw prescription rates climb 18 % within six months of launching a dedicated medical‑science liaison (MSL) network.
Trend #3 – Multi‑Formulation Approaches Boost Adoption
The approval of both a vial and a pre‑filled syringe (PFS) for Idencelt demonstrates the growing importance of flexibility in drug delivery. Surgeons prefer PFS for reduced preparation time and lower contamination risk, while hospitals still rely on vials for bulk purchasing.
According to a 2024 survey by the European Society of Retina Specialists, 62 % of retina clinics rank “ease of administration” as a top factor when selecting a new therapy.
Future Outlook: What’s Next for European Ophthalmic Biosimilars?
1. Expanded Indications – As real‑world evidence accumulates, biosimilars are expected to gain approvals for off‑label uses such as myopic choroidal neovascularization.
2. Digital Health Integration – Remote monitoring platforms that track visual acuity and injection adherence could become bundled services, allowing manufacturers to demonstrate value beyond price.
3. Cross‑Border Price Harmonization – The EU’s forthcoming “single‑price” directive may reduce price fragmentation, giving biosimilars a larger, more predictable market.
Key Takeaways for Stakeholders
- Pharma executives: Prioritize early tender participation and build robust MSL teams to educate ophthalmologists.
- Healthcare payers: Leverage biosimilar discounts to negotiate value‑based contracts tied to visual outcomes.
- Clinicians: Consider biosimilars as first‑line options, especially when supported by strong pharmacovigilance data.
FAQ
- What is a biosimilar?
- A biologic medication that is highly similar to an already approved reference product, with no clinically meaningful differences in safety or efficacy.
- How much cheaper are ophthalmic biosimilars than the originals?
- Typical price reductions range from 30 % to 45 % depending on the market and procurement agreements.
- Will insurance cover biosimilar eye injections?
- In most European countries, national health insurers reimburse biosimilars at the same rate as the reference biologic once they are on the formulary.
- Are there safety concerns with switching to a biosimilar?
- Extensive phase‑III trials and post‑marketing studies have shown comparable safety profiles. Switching is generally considered safe under physician supervision.
Ready to dive deeper into the evolving world of ophthalmic biosimilars? Explore our full analysis and join the conversation in the comments below. Subscribe to our newsletter for weekly updates on biotech breakthroughs.
Worth a look